MedTrace Logo

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

NCT02067793 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2016-03-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.

Conditions

Interventions

DRUG

NRX-1074 1 mg

Single intravenous administration of 1 mg into arm on Day 0

DRUG

Placebo

Single intravenous injection into the arm on Day 0

DRUG

NRX-1074 5 mg

Single intravenous injection of 5 mg into the arm on Day 0

DRUG

NRX-1074 10 mg

Single intravenous injection of 10 mg into the arm on Day 0

Sponsors & Collaborators

  • Naurex, Inc, an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Naurex, Inc, an affiliate of Allergan plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02067793 on ClinicalTrials.gov